DalsnaFinance Account

Quest Diagnostics $DGX

Health Care · Health Care Services · NYSE/NASDAQ

S&P 500 Russell 1000 New Jersey

Create a scorecard

$235.24

+0.33 (+0.14%)

As of Oct 20, 2026, 2:05 PM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 24, 2026, the first target we tracked for DGX.

Key facts

52-week range (closes): $173.49 – $247.45 Lowest close Jan 5, 2026, highest Sep 17, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends: December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since: Dec 12, 2002 · All S&P 500 changes
Analyst coverage: 1 open price target from 1 firm: Truist Securities Approved targets tracked here; see the analyst section below

Quest Diagnostics (DGX) is trading up at $235.24 (+0.14%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on DGX

One firm's current price target on Quest Diagnostics: $250 — 6% above the current $235. Each is tracked to its date and scored the same way a member's call is.

Truist Securities $228 → $250 by Jul 2027 Hold Jul 24, 2026 via Investing.com · Truist Securities's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Quest Diagnostics revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Quest Diagnostics annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$7.21B	$7.40B	$7.53B	$7.73B	$9.44B	$10.8B	$9.88B	$9.25B	$9.87B	$11.0B
Growth (year over year)	−3.7%	+2.6%	+1.7%	+2.6%	+22.1%	+14.3%	−8.4%	−6.4%	+6.7%	+11.8%
Gross profit	$2.90B	$2.68B	$2.60B	$2.69B	$3.63B	$4.21B	$3.43B	$3.05B	$3.24B	$3.67B
Gross margin	40.2%	36.2%	34.6%	34.8%	38.5%	39.0%	34.7%	33.0%	32.9%	33.2%
Operating income	$1.28B	$1.17B	$1.10B	$1.23B	$1.97B	$2.38B	$1.43B	$1.26B	$1.35B	$1.56B
Operating margin	17.7%	15.7%	14.6%	15.9%	20.9%	22.1%	14.4%	13.6%	13.6%	14.1%
Net income	$645.0M	$772.0M	$736.0M	$858.0M	$1.43B	$2.00B	$946.0M	$854.0M	$871.0M	$992.0M
Net margin	8.9%	10.4%	9.8%	11.1%	15.2%	18.5%	9.6%	9.2%	8.8%	9.0%
EPS (diluted)	$4.51	$5.50	$5.29	$6.28	$10.47	$15.55	$7.97	$7.49	$7.69	$8.75
Balance sheet
Cash and equivalents	$359.0M	$137.0M	$135.0M	$1.19B	$1.16B	$872.0M	$315.0M	$686.0M	$549.0M	$420.0M
Total assets	$10.1B	$10.5B	$11.0B	$12.8B	$14.0B	$13.6B	$12.8B	$14.0B	$16.2B	$16.2B
Total liabilities	$5.44B	$5.55B	$5.74B	$7.16B	$7.22B	$7.13B	$6.91B	$7.68B	$9.34B	$9.02B
Long-term debt	$3.73B	$3.75B	$3.43B	$3.97B	$4.01B	$4.01B	$3.98B	$4.41B	$5.62B	$5.17B
Shareholders' equity	$4.63B	$4.92B	$5.22B	$5.64B	$6.76B	$6.44B	$5.89B	$6.31B	$6.78B	$7.17B
Cash flow
Operating cash flow	$1.12B	$1.18B	$1.20B	$1.24B	$2.00B	$2.23B	$1.72B	$1.27B	$1.33B	$1.89B
Capital expenditure	$293.0M	$252.0M	$383.0M	$400.0M	$418.0M	$403.0M	$404.0M	$408.0M	$425.0M	$527.0M
Free cash flow	$823.0M	$923.0M	$817.0M	$843.0M	$1.59B	$1.83B	$1.31B	$864.0M	$909.0M	$1.36B
Dividends paid	$223.0M	$247.0M	$266.0M	$286.0M	$297.0M	$309.0M	$305.0M	$314.0M	$331.0M	$353.0M
Share buybacks	$590.0M	$465.0M	$322.0M	$353.0M	$325.0M	$2.20B	$1.41B	$275.0M	$151.0M	$450.0M

RevenueNet incomeNet margin (right axis, %)

Quest Diagnostics quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$2.49B	$2.62B	$2.65B	$2.76B	$2.82B	$2.81B	$2.90B	$3.04B
Growth (year over year)	+8.4%	+14.6%	+12.1%	+15.2%	+13.2%	+7.1%	+9.2%	+10.2%
Gross profit	$811.0M	$858.0M	$863.0M	$943.0M	$949.0M	$910.0M	$942.0M	$1.03B
Gross margin	32.6%	32.7%	32.5%	34.2%	33.7%	32.4%	32.5%	33.7%
Operating income	$330.0M	$361.0M	$346.0M	$438.0M	$386.0M	$386.0M	$399.0M	$459.0M
Operating margin	13.3%	13.8%	13.0%	15.9%	13.7%	13.8%	13.8%	15.1%
Net income	$226.0M	$222.0M	$220.0M	$282.0M	$245.0M	$245.0M	$252.0M	$320.0M
Net margin	9.1%	8.5%	8.3%	10.2%	8.7%	8.7%	8.7%	10.5%
EPS (diluted)	$1.99	$1.95	$1.94	$2.47	$2.16	$2.18	$2.24	$2.84
Balance sheet
Cash and equivalents	$764.0M	$549.0M	$188.0M	$319.0M	$432.0M	$420.0M	$393.0M	$626.0M
Total assets	$16.1B	$16.2B	$15.8B	$16.0B	$16.2B	$16.2B	$16.7B	$16.9B
Total liabilities	$9.25B	$9.34B	$8.84B	$8.70B	$8.90B	$9.02B	$9.01B	$9.12B
Long-term debt	$5.65B	$5.62B	$5.86B	$5.17B	$5.17B	$5.17B	$5.16B	$5.63B
Shareholders' equity	$6.81B	$6.78B	$6.93B	$7.23B	$7.26B	$7.17B	$7.37B	$7.52B
Cash flow
Operating cash flow	$356.0M	$464.0M	$314.0M	$544.0M	$563.0M	$465.0M	$278.0M	$597.0M
Capital expenditure	$106.0M	$123.0M	$117.0M	$108.0M	$144.0M	$158.0M	$114.0M	$138.0M
Free cash flow	$250.0M	$341.0M	$197.0M	$436.0M	$419.0M	$307.0M	$164.0M	$459.0M
Dividends paid	$84.0M	$84.0M	$84.0M	$90.0M	$89.0M	$90.0M	$88.0M	$96.0M
Share buybacks	—	$151.0M	—	—	$150.0M	$300.0M	—	—

From Quest Diagnostics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Quest Diagnostics vs the Health Care sector and the S&P 500

Quest Diagnostics's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Quest Diagnostics compared with the median Health Care company and the median S&P 500 company
Measure	Quest Diagnostics	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	+11.8%	+7.1%	+7.0%
Net margin, latest fiscal year	9.0%	13.1%	13.0%
Share price change, 1 year	+23.4%	+19.8%	+5.6%

Quest Diagnostics: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Quest Diagnostics included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.

About Quest Diagnostics

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Source: Wikipedia — Quest Diagnostics